Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208285 | 0.98 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL723040 | 0.96 | CTNNB1 (0.47) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8372539 | 0.91 | CTNNB1 (0.44) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8374373 | 0.91 | CTNNB1 (0.44) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8379526 | 0.91 | CTNNB1 (0.44) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8601698 | 0.91 | CTNNB1 (0.44) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| Bromide SCHEMBL27853358 | 0.84 | SNCA (0.38) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL8379528 | 0.82 | CTNNB1 (0.43) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| Bromide SCHEMBL9954359 | 0.81 | HIF1A (0.48) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| Bromide SCHEMBL2446627 | 0.81 | HIF1A (0.55) | CYP1A2CYP2C19CYP2D6HIF1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9314467-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970272-A1 | GLYCOSIDASE INHIBITORS | Merck Patent GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-8420863-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| EP-2076124-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2008131368-A2 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-0662972-B1 | 3-,8-SUBSTITUTED DEUTEROPORPHYRINE DERIVATIVES, PHARMACEUTICALS CONTAINING THEM AND METHODS OF PRODUCING THEM | DIAGNOSTIKFORSCHUNG INST (DE) | 2002-10-30 | — | — | EP | disclosed |
| US-5849259-A | 3-,8-substituted deuteroporphyrin derivatives, pharmaceutical agents containing the latter and process for their production | INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5684185-A | MULTISTAGE REACTION OF SULFIDING, REACTION WITH YLIDE, HYDROLYSIS, HYDROGENATION AND OXIDATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0662972-A1 | 3-,8-SUBSTITUTED DEUTEROPORPHYRINE DERIVATIVES, PHARMACEUTICALS CONTAINING THEM AND METHODS OF PRODUCING THEM | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007894-A1 | 3-,8-SUBSTITUTED DEUTEROPORPHYRINE DERIVATIVES, PHARMACEUTICALS CONTAINING THEM AND METHODS OF PRODUCING THEM | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031871-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | CTNNB1 3072/4885TDP1 295/4885CYP1A2 416/4885 |
| US-10301299-B2 | Glycosidase inhibitors | GAA, BACE1, GBA3 | CTNNB1 3072/4885TDP1 295/4885CYP1A2 416/4885 |
| US-20120129860-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | CTNNB1 2785/4885TDP1 272/4885CYP1A2 4246/4885 |
| US-20180093977-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | CTNNB1 3072/4885TDP1 295/4885CYP1A2 416/4885 |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | CTNNB1 2785/4885TDP1 272/4885CYP1A2 4246/4885 |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | CTNNB1 2785/4885TDP1 272/4885CYP1A2 4246/4885 |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ALDH1A2, STARD3, TXNRD2 | CTNNB1 2785/4885TDP1 272/4885CYP1A2 4246/4885 |
| US-20090170841-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | CTNNB1 2785/4885TDP1 272/4885CYP1A2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.